Announced
Synopsis
Inflexion-backed Rosemont, a pharmaceutical company, agreed to acquire Lucis Pharma, a specialist pharmaceutical business in the UK. Financial terms were not disclosed. "As well as continuing to broaden our portfolio and add to our strong growth globally, this acquisition also gives access to pipeline products and developer relationships to accelerate our entry into new product areas such as sachets. We will continue creating innovative solutions that meet the needs of dysphagic patients and establish best practice for their care," Howard Taylor, Rosemont CEO.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.